Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance (TRIM-IR)
Treatment Response to Incretin Mimetics in Non-diabetic Obese Patients With and Without Insulin Resistance (TRIM-IR)
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear.
The TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, and adipose tissue function during the first 16 weeks of semaglutide therapy. The study will also explore molecular markers of adipose tissue dysfunction, focusing on the transition from dysfunctional to healthy adipose tissue.
The investigators hypothesize, that individuals with lower IR will experience greater weight loss than those with higher IR, and that the glucose infusion rate (GIR) during hyperinsulinemic euglycemic clamp testing will correlate with weight loss variability. Secondary objectives include comparing changes in fat and lean mass, reductions in visceral fat, and improvements in adipose tissue function before and after 16 weeks of treatment. Exploratory analyses will assess adipocyte subpopulations and their response to insulin sensitivity changes.
A total of 40 participants, equally distributed by gender, will be enrolled to ensure statistical power for detecting clinically relevant differences. The study aims to optimize semaglutide use for personalized obesity treatment and provide insights into the relationship between obesity, insulin resistance, and adipose tissue plasticity, with implications for improving obesity management and cardiovascular health outcomes.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Canton of Aargau
-
Aarau, Canton of Aargau, Suíça, 5001
- Cantonal Hospital Aarau
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The investigators plan to include a total of 40 non-diabetic, obese individuals that will undergo treatment with semaglutide as a weight-loss intervention independent of our observational study. To avoid a highly heterogeneous participant group, inclusion in the study will be limited to individuals with a BMI between 30 and 40 kg/m². Patients with a prediabetic state will not be excluded.
Descrição
Inclusion Criteria:
-
Age between 18 and 60 years
-
BMI 30 - 40 kg/m2
a. Participants must meet the eligibility criteria for coverage under the KVG (Federal Health Insurance Act) and the Specialties List, which include a weight-related comorbidity (arterial hypertension, dyslipidemia) for participants with a BMI of 30- 35 kg/m2
-
Planned therapy with semaglutide as a weight loss intervention
-
No known presence of a diabetic state
-
Ability to understand and sign a Patient Information and Consent Form
Exclusion Criteria:
-
Pregnancy or active breast feeding
- Therapy with semaglutide is not approved for use during pregnancy or while breastfeeding, as its safety and efficacy in these conditions have not been established.
- Pregnancy is an exclusion criterion for the planned investigations to avoid placing pregnant individuals under unnecessary physical or psychological stress that could pose risks to both the individual and the fetus.
-
Medication and/or pathologies that prevent the safe execution of the fat tissue biopsies (e.g. allergy towards local anesthetics, disorders of coagulation, treatment with anticoagulants)
-
Medical conditions that prevent examinations and testing (e.g. epilepsia, symptomatic cardiovascular disease)
-
History of or planned bariatric surgery
-
HbA1c ≥ 6.5% as measured by the central laboratory at screening
-
Fasting plasma-glucose >7.0 mmol/l
-
History of type 1 or type 2 diabetes mellitus
-
Treatment with glucose-lowering agent(s) (e.g. Metformin) within 90 days before screening
-
Treatment with a GLP-1 (glucagon like peptide 1) receptor agonist within 180 days before screening
-
A self-reported change in body weight >5% within 90 days before screening
-
Active malignancy (<2a since remission)
-
Treatment with any medication for the indication of obesity within the past 90 days before screening
-
Uncontrolled thyroid disease, defined as thyroid stimulating hormone (TSH) > 10 mIU/L or < 0.4 mIU/L as measured by the central laboratory at screening
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: CASE_ONLY
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Non-diabetic obese individuals on semaglutide for weight loss
Non-diabetic obese individuals with planned semaglutide treatment as a weight loss intervention |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Mudança no peso corporal (%)
Prazo: 16 semanas
|
16 semanas
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in fat mass (%)
Prazo: 16 weeks
|
measured by DEXA (dual energy x-ray absorptiometry) |
16 weeks
|
|
Change in lean mass (%)
Prazo: 16 weeks
|
measured by DEXA |
16 weeks
|
|
Change in abdominal visceral fat area (in cm2)
Prazo: 16 weeks
|
measured by DEXA |
16 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in cell size of adipose tissue after 16 weeks of semaglutide treatment
Prazo: 16 weeks
|
The size of adipocytes is a direct measure of adipose tissue quality and function. It will be evaluated through histological examinations. |
16 weeks
|
|
Changes in cell distribution of adipose tissue after 16 weeks of semaglutide treatment
Prazo: 16 weeks
|
Changes in the distribution of adipocytes and other components of adipose tissue (e.g. macrophages, progenitors) serve as a direct measure of adipose tissue quality and function. It will be evaluated through histological examinations. |
16 weeks
|
|
Changes in signs of fibrosis in adipose tissue after 16 weeks of semaglutide treatment
Prazo: 16 weeks
|
Signs of fibrosis are a direct measure of adipose tissue quality and function. They will be evaluated through histopathological analysis. |
16 weeks
|
|
Changes in inflammatory activity of adipose tissue after 16 weeks of semaglutide treatment
Prazo: 16 weeks
|
Inflammatory activity, measured by the number and type of white blood cells infiltrating adipose tissue, is a direct way to assess adipose tissue quality and function. It will be evaluated by quantifying inflammatory cells within the tissue. |
16 weeks
|
|
Change in adipokine secretion pattern after 16 weeks of semaglutide treatment
Prazo: 16 weeks
|
The adipokine-secretion pattern is an indirect way to assess adipose tissue quality and function. We will analyze leptin, adipokines, and other relevant markers in blood samples and potentially in adipose tissue from strong or weak responders to identify patterns that may help predict significant changes or the absence of response. |
16 weeks
|
|
Change in systemic inflammation after 16 weeks of semaglutide treatment
Prazo: 16 weeks
|
Adipose tissue dysfunction can contribute to systemic inflammation, making it an indirect measure of adipose tissue quality. Serum levels of systemic inflammatory markers such as C-reactive protein (CRP), interleukins, and tumor necrosis factor-alpha (TNF-α) will be assessed before and after 16 weeks of semaglutide treatment. |
16 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Christian Wolfrum, Prof. Dr., ETH Zurich
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios Nutricionais
- Doenças Metabólicas
- Supernutrição
- Peso corporal
- Alterações de Peso Corporal
- Distúrbios do Metabolismo da Glicose
- Hiperinsulinismo
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Excesso de peso
- Obesidade
- Perda de peso
- Resistência a insulina
Outros números de identificação do estudo
- 2024-02395
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .